Radioimmunotherapy of lymphoma: Bexxar and Zevalin
- PMID: 20113680
- DOI: 10.1053/j.semnuclmed.2009.11.002
Radioimmunotherapy of lymphoma: Bexxar and Zevalin
Abstract
Radioimmunotherapy is a form of targeted radionuclide therapy that uses a monoclonal antibody to deliver localized radiation. It is most appropriate for treatment of multiple tumor sites that cannot be readily excised surgically or irradiated using external beam radiation or brachytherapy. At present, 2 products, Bexxar ((131)I-tositumomab and unlabeled tositumomab, GlaxoSmithKline, Triangle Park, NC) and Zevalin ((90)Y-ibritumomab tiuxetan and unlabeled rituximab, Spectrum Pharmaceuticals, Irvine, CA and Cell Therapeutics, Seattle, WA) are approved for treatment of non-Hodgkin's lymphoma in certain clinical situations in the United States and Canada. Zevalin is available also in Europe, and there are plans to make both agents more widely available. The therapeutic dose to be used depends upon a number of patient-specific variables. Both regimen achieve a complete response or partial response in approximately 3 of 4 patients, with a duration of remission lasting many years in some cases. This article reviews the basis for dose selection, the nuclear medicine procedures involved, the results obtained to date, and issues related to patient and staff safety.
Similar articles
-
Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues.Cancer Treat Rev. 2004 Apr;30(2):165-72. doi: 10.1016/j.ctrv.2003.07.006. Cancer Treat Rev. 2004. PMID: 15023434 Review.
-
Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.Semin Radiat Oncol. 2007 Jul;17(3):176-83. doi: 10.1016/j.semradonc.2007.02.003. Semin Radiat Oncol. 2007. PMID: 17591564 Review.
-
Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43. doi: 10.1053/j.seminoncol.2005.01.012. Semin Oncol. 2005. PMID: 15786024
-
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.
-
Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.Biotechnol Annu Rev. 2004;10:265-95. doi: 10.1016/S1387-2656(04)10011-2. Biotechnol Annu Rev. 2004. PMID: 15504711 Review.
Cited by
-
Cancer stratification by molecular imaging.Int J Mol Sci. 2015 Mar 4;16(3):4918-46. doi: 10.3390/ijms16034918. Int J Mol Sci. 2015. PMID: 25749472 Free PMC article. Review.
-
Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.World J Nucl Med. 2012 Sep;11(3):110-6. doi: 10.4103/1450-1147.103409. World J Nucl Med. 2012. PMID: 23372448 Free PMC article.
-
Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.Indian J Med Res. 2016 Jan;143(1):57-65. doi: 10.4103/0971-5916.178593. Indian J Med Res. 2016. PMID: 26997015 Free PMC article.
-
Targeted Radionuclide Therapy: Practical Applications and Future Prospects.Biomark Cancer. 2016 May 18;8(Suppl 2):35-8. doi: 10.4137/BIC.S31804. eCollection 2016. Biomark Cancer. 2016. PMID: 27226737 Free PMC article. Review.
-
Algorithms and Analyses for Joint Spectral Image Reconstruction in Y-90 Bremsstrahlung SPECT.IEEE Trans Med Imaging. 2020 May;39(5):1369-1379. doi: 10.1109/TMI.2019.2949068. Epub 2019 Oct 23. IEEE Trans Med Imaging. 2020. PMID: 31647425 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
